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Abstract
Background: The prevalence of hepatitis B virus infection in Greece has been decreasing over the
last decades. However, recent epidemiological data are lacking.
Methods: We studied 1,840 Army recruits from 05/2004 until 10/2005, and performed serological
testing for HBsAg, anti-HBsAg, and anti-HBcAg. We also examined their association with several
factors, including age, residential area, socioeconomic class, and educational level.
Results: Mean age (± SD) of the recruits was 20.5 (± 2.1) years. Antibodies to HBV core antigen
[anti-HBcAg (+)] were found in 31 (1.68%) of 1,840 participants. Only 6 (0.32%) were HBsAg (+)/
anti-HBsAg (-)/anti-HBcAg (+), while 21 (1.14%) were HBsAg (-)/anti-HBsAg (+)/anti-HBcAg (+),
and 4 (0.22%) were HBsAg (-)/anti-HBsAg (-)/anti-HBcAg (+). Overall, 1,144 recruits (62.17%) had
antibodies against HBsAg [HBsAg (-)/anti-HBsAg (+)/anti-HBcAg (-)]; 665 recruits (36.14%) had
undetectable anti-HBsAg levels. Multivariable analysis showed that younger age (OR: 0.87; 95% CI:
0.82–0.92) and advanced educational level (OR: 1.59; 95% CI: 1.32–1.93) were independently
associated with serologic evidence suggestive of previous HBV vaccination.
Conclusion: We document a further decline of the prevalence of chronic HBV infection among
Greek military recruits, a fact that may support the effectiveness of the ongoing immunization
programme.
Background
Hepatitis B is a well-recognized global public health prob-
lem. It is estimated that nearly 2 billion people around the
world have serologic evidence of past or present hepatitis
B virus (HBV) infection, while 350 million people are
chronically infected [1]. Ongoing efforts towards the
decrease of the prevalence of HBV infection have led to
implementation of vaccination in childhood. Given the
fact that HBV is the main etiologic factor for hepatocellu-
lar carcinoma, epidemiological studies are needed to doc-
ument the compliance to and effectiveness of HBV
vaccination programs in various populations and settings
in order to establish a cost-effective health policy.
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ate prevalence of chronic HBV infection, as seropositivity
for HBV surface antigen (HBsAg) was in the range of 2%
to 7% [2-5]. However, epidemiological studies in the pre-
vious decade showed a decline of this prevalence to the
levels of low endemicity – about 0.9% – partially attrib-
uted to changes of the socioeconomic conditions [3,6]. In
addition, HBV vaccination programs were gradually
implemented. Most private paediatricians, who adminis-
ter more than 60% of all childhood vaccinations in
Greece, began vaccinating children against HBV in their
practices in 1993. Therefore, HBV vaccination had already
been administered to 36% and 56% of children (aged 5–
6 years' old) entering primary school in 1995 and 1997,
respectively [7]. The government decided to launch a
national HBV immunization programme and raise the
financial burden of its implementation in 1998 [7]. At the
same time, efforts were made to offer HBV vaccination to
high-school students that apparently had not been immu-
nized against HBV earlier in their life. Nowadays, vaccina-
tion has been considered as mandatory for all newborns
and children entering puberty that were not immunized
earlier in their life (about 12 years' old) [7].
In order to provide further information on current HBV
epidemiology in Greece, we conducted a prospective
study of young military recruits joining the Hellenic Army
from May 2004 to October 2005. We performed serologi-
cal testing for HBV infection markers and searched for




The study took place in Sparta, the historic capital city of
ancient Spartans, where the Supply and Transportation
Corps Training Centre of the Hellenic Army is currently
based. The study population consisted of 1,840 men, aged
17–34 years, who were transferred to Sparta in order to
receive training in food handling and meal preparation.
The study protocol was approved by the Medical Directo-
rate of the Hellenic Army General Staff.
Laboratory testing
A blood sample was taken from all recruits, as part of their
standard evaluation procedure in order to obtain a health
certificate. Blood sampling was performed from May 2004
to October 2005, on the occasion of recruit enlistment
and just for the purpose of this study. Ten milliliters of
venous blood were collected in a dry test tube from each
soldier. Blood samples were transported to the Microbiol-
ogy Laboratory of 401 Army General Hospital of Athens,
within 3 hours, for processing.
Sera were separated by centrifugation and kept frozen at -
20°C, until tested. All sera were tested for hepatitis B sur-
face antibody (anti-HBsAg) by a Microparticle Enzyme
Immunoassay (MEIA) (AxSym AUSAB, Abbott Laborato-
ries Diagnosis Division, Abbott Park, IL, USA), hepatitis B
surface antigen (HBsAg), and hepatitis B core antibody
(anti-HBcAg) by MEIA (AxSym HBsAg (V2) and AxSym
CORE, Abbott Laboratories Diagnosis Division, Abbott
Park, IL, USA, respectively), according to the manufac-
turer's instructions. All positive samples for HBsAg were
analyzed twice with the same test. A positive test for anti-
bodies to hepatitis B core antigen was considered to be
merely suggestive of a history of HBV infection, while
chronic HBV infection was defined by the simultaneous
presence of both HBsAg and antibodies to hepatitis B core
antigen. An anti-HBsAg titer of greater than 10 mIU/ml
was considered protective [8,9]. All study participants
were informed on test results by means of personal inter-
views, while infected patients were examined and appro-
priately counseled by the staff of the Internal Medicine
and Infectious Diseases Department of 401 Army General
Hospital of Athens.
Data collection
Epidemiological data regarding age, geographic area of
residence, educational level and prior occupation were
collected by means of personal interviews. For the pur-
poses of this analysis the residential areas were divided in
urban (including the seven major cities of Greece, namely
Athens, Thessaloniki, Patra, Iraklion, Larisa, Ioannina and
Alexandroupolis) and rural (including all other smaller
cities, towns and villages). The educational level stratifica-
tions we used were: elementary school, high school, voca-
tional education institute, technical educational institute,
and university.
The socioeconomic level was determined on the basis of
the occupation prior to recruitment to the Army using the
Erikson-Goldthorpe Portocarero (EGP) social class
scheme [10]. According to this scheme, occupations are
grouped in seven classes, with class I including higher-
grade professionals, class II lower-grade professionals
administrators, class III routine non-manual employees,
class IV small proprietors, artisans, farmers and small-
holders, class V lower-grade technicians, class VI manual
workers, and class VII including unskilled manual workers
and agricultural workers. We performed a slight modifica-
tion of the EGP social class scheme, by adding one more
class in order to include persons unemployed at the time
of military recruitment. The recruits' vaccination history
was unknown, as no medical records were available for
review. Finally, demographical data were available for a
subset of the participants.Page 2 of 6
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Chi-square test was used in the bivariable analysis for the
comparison of the prevalence of HBV serologic markers in
various subgroups based on discrete characteristics. Nor-
mality was assessed and t-test or a non-parametric test was
used for normally and non-normally distributed continu-
ous variables. A p-value <0.05 was considered statistically
significant. A backward multivariable logistic regression
model was used in order to estimate relationships
between recruits' epidemiological factors and HBV infec-
tion markers. Data were analyzed using SPSS for Windows
version 12.0 (SPSS Inc, Chicago, IL, USA).
Results
All recruits were male, and their mean age (± SD) was 20.5
(± 2.1) years. Of the 1,840 study participants, 1,144
(62.17%) had antibodies against HBsAg [HBsAg (-)/anti-
HBsAg (+)/anti-HBcAg (-)], while 665 recruits (36.14%)
had undetectable anti-HBsAg levels. It should be noted
that testing of the HBV serologic status is recommended in
selected Greek army training centers and, notwithstand-
ing the limitations of anti-HBsAg as a marker for vaccina-
tion status, the recruits found to have undetectable titers
of anti-HbsAg are advised to receive HBV vaccination on a
personal basis after consultation with a primary physi-
cian.
Antibodies to HBV core antigen were found in 31 recruits,
or 1.68% of the total population under study (1,840 par-
ticipants). Twenty-one of them (1.14% of the total popu-
lation) were HBsAg (-)/anti-HBsAg (+)/anti-HBcAg (+),
and 4 (0.22%) were HBsAg (-)/anti-HBsAg (-)/anti-HBcAg
(+). Only 4 recruits were anti-HBs (-)/HBsAg (-). The over-
all prevalence of HbsAg carriage was 0.32%, or, 6 out of
1,840 participants. The results of the above-mentioned
serologic analysis are shown in Table 1.
Analysis of data from 6 recruits who tested positive for
HBsAg showed that 3 of them were 19 years old, 1 was 21
years old and 2 were 22 years old. Interestingly, 5 out of 6
were from rural Greece, and 2 were unemployed, while
the other 4 belonged to classes VI and VII of the EGP
social class scheme. No formal statistical analysis of these
data was performed due to the small number of persons
with HbsAg seropositivity.
The bivariable analysis we performed to investigate possi-
ble relationship of the available epidemiological charac-
teristics with the presence of anti-HBcAg seropositivity
yielded no statistically significant associations (p = 0.60
for socioeconomic class, p = 0.24 for residential area, p =
0.77 for educational level, and p = 0.29 for age).
A backward multivariable logistic regression model
showed that younger age (OR: 0.87; 95% CI: 0.82–0.92)
and advanced educational level (OR: 1.59; 95% CI: 1.32–
1.93) were independently associated with anti-HbsAg
seropositivity [anti-HBs (+)/anti-HBcAg (-)/HBsAg (-)].
We display this inverse correlation of anti-HBsAg seropos-
itivity with age in Figure 1. No association was found with
the area of residence and the socioeconomic class.
Discussion
The main finding of our study is that compared with pre-
vious epidemiological data regarding HBV infection in
Army recruits in Greece, we documented a further reduc-
tion of the prevalence of seropositivity for HBsAg during
the last decade. In 1971, the HBsAg seroprevalence among
6,708 Hellenic Air Force recruits, tested consecutively and
without any selection, was 4.9% [5]. In 1998, the overall
prevalence of HBsAg positivity in 1,050 male navy recruits
was 0.95% [3]. Our findings demonstrate a continuing
trend in seroepidemiology of HBV in Greece, about 10
years after the establishment of mandatory vaccination for
infants and adolescents not previously immunized. The
results of our study are in accordance with a very recently
published study in 13,581 Greek women at reproductive
age (16–45 years old) in which HBsAg seroprevalence of
0.29% was reported [6].
It is noteworthy that the frequency of anti-HBsAg seropos-
itivity was more common (62.2%) among our study sub-
jects compared to the ones reported from previous studies
in Greece. Serologic indices denoting previous vaccina-
tion were found in 32.6% of navy recruits in a study per-
formed in 1998 [3], while only 12.2% of a general
population (over 18 years old) studied in south-western
Greece had such indices in 2002 [4]. The higher degree of
anti-HBsAg seropositivity observed in our study may be a
reflection of the success of the ongoing vaccination pro-
Table 1: Hepatitis B virus (HBV) infection serologic markers in 1,840 Greek army recruits (2004–2005).
HBV markers N % of the study population
anti-HBcAg (+) 31 1.68
HBsAg (+)/anti-HBsAg (-) 6 0.32
anti-HBsAg (+)/HBsAg (-) 21 1.14
anti-HBsAg (-)/HbsAg (-) 4 0.22
anti-HBsAg (+)/anti-HBcAg (-)/HBsAg (-) 1,144 62.17
anti-HBsAg (-)/anti-HBcAg (-)/HBsAg (-) 665 36.14Page 3 of 6
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should be taken in order to achieve universal vaccination.
Another interesting finding of our study is that younger
age and higher educational level were independently asso-
ciated with anti-HBsAg seropositivity. Even though the
unavailability of the vaccination records does not allow us
to refute the possibility that younger and more educated
subjects were vaccinated at a time closer to their recruit-
ment into the military, we believe that another explana-
tion of this finding may be that the integration of HBV
vaccination into routine vaccination schedules rendered
results mainly in younger adolescents. Even though it is
likely that the higher probability of vaccination is not
actually related to the level of education of the recruits but
rather to the higher educational level of their parents (i.e.
more educated parents are more likely to vaccinate their
children), the association between a higher educational
level and vaccination rates observed in our study seems to
be strong and it has also been noted in studies of other
populations and for other types of vaccines. Our data sug-
gest that stronger efforts should be made for implement-
ing vaccination policies in unvaccinated adults, especially
those with a low educational level.
Our study has several limitations. First, it should be noted
that each study has its own "target" population, setting
and methodology. For example, our analysis is focused at
a population with specific characteristics, namely young
male military recruits. Thus, are findings cannot be
directly comparable with previous studies nor extrapo-
lated to women or to special populations at high risk for
HBV infection, such as intravenous drug users, sex work-
ers, as well as hemodialysis patients and multiply trans-
fused patients. In addition, our analysis did not include
immigrants who do not have military obligations; some
Prevalence of anti-HbsAg (+) in correlation with recruits' ageFigur  1
Prevalence of anti-HbsAg (+) in correlation with recruits' age.Page 4 of 6
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HBV. A high prevalence of HBV infection in refugees has
been reported in previous studies [11,12]. There is a con-
cern that, unless targeted vaccination programs for these
communities are implemented, there will be an increase
in the HBV incidence in the general population in the
future. Also, we did not determine the viral load of the six
HBsAg (+) recruits and we did not perform S-region
sequencing in order to identify possible escape mutants.
Another limitation of our findings is that the recruits' vac-
cination records were not available for further analysis,
due to the special circumstances under which this study
was conducted (limited time-frame in a military unit).
This makes difficult the interpretation of the HBV sero-
logic profile in some of the recruits. For example, it is
known that the levels of anti-HbsAg decrease over time in
vaccinated persons without this decline being associated
with a loss of protection against HBV [13]. It is possible
that some recruits with undetectable levels of anti-HBsAg
were in fact vaccinated and, therefore, protected against
HBV infection. Finally, we considered the presence of
antibodies to hepatitis B core antigen in 31 recruits as an
indication of previous HBV infection. This seems to be
true for the 27 out of the 31 recruits that had other mark-
ers of HBV infection as well [6 with HBsAg (+) and 21
with anti-HBsAg (+)]. However, the 4 recruits with the
"anti-HbcAg (+) alone" profile may fall under one of the
following possibilities: (i) false positive cases, (ii) the
"window phase" of an acute HBV infection, (iii) an HBV
infection that resolved years or decades earlier, (iv) an
unresolved chronic HBV infection with low grade, possi-
bly intermittent virus production and detectable serum or
liver HBV-DNA, and (v) suppression of HBV replication
by a simultaneous HCV co-infection [14].
Despite the above limitations, the results of this study
may reflect the continuing progress towards the eradica-
tion of HBV transmission in Greece through universal
immunization. In recent years, the implementation of a
vaccination program against HBV, medical precautions,
screening of blood donors, and modifications in socioe-
conomic conditions, resulted in significant decline in
HBV infection in Greece. Nevertheless, demographic
changes resulting from the entrance in Greece of immi-
grants and repatriated people, mainly from countries of
the Eastern Europe, as well as refugees from various coun-
tries with high endemicity for HBV infection, in the last
decade, may lead to alterations of the epidemiology of
HBV infection in our country. Therefore, the continuing
surveillance of trends in the epidemiology of this inflec-
tion is of paramount importance for the design of effective
vaccination policies in the future.
Conclusion
Our data suggest that that the National Immunization
Program for hepatitis B has been largely successful in
reducing the prevalence of hepatitis B infection and
increasing immunity levels in the population. However,
hepatitis B virus infection still remains a serious public
health problem. Therefore, there is a need to strengthen
the hepatitis B immunization program to reach universal
vaccination. The goal of eliminating HBV transmission is
attainable and efforts towards this direction should be a
top public health priority.
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